Vieri S.
- Country
- Italy
- Department
- Oncologia
Research Overview
- Phase II Study of Niraparib and Dostarlimab in Advanced NSCLC or Malignant Pleural Mesothelioma with PD-L1 Expression and HRR Gene Mutations
- Efficacy of Osimertinib in Treatment-Naïve Patients with EGFR Mutant NSCLC Stratified by TP53 Mutational Status
- Phase II Evaluation of Overall Survival in Relapsed Stage III NSCLC with Durvalumab and Chemotherapy Post-Chemoradiotherapy and Durvalumab Maintenance
Data & Insights
Has run more than one trial at 17 of 50 partner sites.
Specializations
Thoracic Oncology
The investigator specializes in treating non-small cell lung cancer (NSCLC), with particular focus on advanced and locally advanced disease states. Their expertise extends to managing patients with specific genetic profiles, including EGFR mutations and TP53 mutational status.
- Stage III NSCLC Management
- Advanced NSCLC Treatment
- Genetic Mutation Analysis
Their work includes evaluation of targeted therapies and maintenance treatments for thoracic malignancies.
Immunotherapy Applications
The investigator focuses on immunotherapy approaches in thoracic cancers, particularly studying treatments such as durvalumab and pembrolizumab. Their research encompasses maintenance therapy strategies and combination treatment protocols.
- Maintenance Immunotherapy
- Chemoimmunotherapy Combinations
- PD-L1 Expression Studies
Their expertise includes evaluating immune checkpoint inhibitors in various treatment settings.
Rare Thoracic Malignancies
The investigator has expanded their research scope to include malignant pleural mesothelioma, investigating novel therapeutic combinations. Their work involves evaluating targeted treatments in combination with immunotherapy approaches.
- Mesothelioma Treatment
- Combined Modality Therapy
- HRR Gene Mutations
Their research includes exploration of biomarker-driven treatment strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.